![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Alibaba
BABA
NVIDIA
NVDA
Qualcomm
QCOM
ASML Holding
ASML
Broadcom
AVGO
US Stock MarketDetailed Quotes
CLSD Clearside Biomedical
- 0.855
- -0.015-1.74%
Trading Mar 13 11:50 ET
64.85MMarket Cap-1.90P/E (TTM)
0.890High0.855Low41.13KVolume0.880Open0.870Pre Close35.90KTurnover0.06%Turnover RatioLossP/E (Static)75.84MShares1.80052wk High-1.86P/B59.83MFloat Cap0.77452wk Low--Dividend TTM69.97MShs Float25.080Historical High--Div YieldTTM4.01%Amplitude0.560Historical Low0.872Avg Price1Lot Size
Clearside Biomedical Stock Forum
Sign in to post a comment
$Clearside Biomedical (CLSD.US)$
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3
1
1
$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMDClearside Biomedical (NASDAQ: CLSD)has announced successful End-of-Phase 2 meeting results with the FDA regarding CLS-AX for wet AMD treatment. The company received alignment on its Phase 3 program design for two concurrent non-inferiority pivotal trials.
The proposed Phase 3 trials will feature:
~450 treatment-naïve ...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMDClearside Biomedical (NASDAQ: CLSD)has announced successful End-of-Phase 2 meeting results with the FDA regarding CLS-AX for wet AMD treatment. The company received alignment on its Phase 3 program design for two concurrent non-inferiority pivotal trials.
The proposed Phase 3 trials will feature:
~450 treatment-naïve ...
1
$Clearside Biomedical (CLSD.US)$ Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
2 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -
- Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development
2 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -
- Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
65
7
4
2
$Clearside Biomedical (CLSD.US)$
China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market?
China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market?
$Clearside Biomedical (CLSD.US)$
Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Thursday, 20th February at 7:05 am
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Thursday, 20th February at 7:05 am
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
1
$Clearside Biomedical (CLSD.US)$
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients
1
$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Tuesday, 28th January at 7:05 am
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature
CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
- CLS-AX Targets Flexible Dosing of Biologics with Duration of Tyrosine Kinase Inhibitors -
ALPHARETTA, Ga., ...
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Tuesday, 28th January at 7:05 am
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature
CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
- CLS-AX Targets Flexible Dosing of Biologics with Duration of Tyrosine Kinase Inhibitors -
ALPHARETTA, Ga., ...
1
$Clearside Biomedical (CLSD.US)$ Reuters· just
Clearside Biomedical Announces Its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Clearside Biomedical Announces Its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Viking Trader : so dead